Abstract
Epithelial ovarian cancer (EOC) accounts for approximately 80-90% of all ovarian cancers, and 75% of the patients are diagnosed with advanced disease (stage III and IV). Front-line systemic chemotherapy improves survival in women with advanced EOC; however, tumor recurrence occurs in almost all advanced EOC patients at a median of 15 months from diagnosis, and 5-year survival is estimated at 10 to 30%. Additionally, around 20% of patients do not respond to standard front-line therapy. Tumoral angiogenesis plays an important role in the pathogenesis of EOC, and its inhibition might improve survival in patients with advanced EOC. High-grade EOC is characterized by overexpression of vascular endothelial growth factor (VEGF), which drives dysfunctional tumor-associated angiogenesis, contributing to high interstitial pressure and increased vascular permeability. Diverse anti-angiogenic drugs are under investigation, and direct targeting of this pathway can be achieved by sequestration of VEGF protein using monoclonal antibodies (bevacizumab) or engineered binding site molecules (aflibercept), blockade of the VEGF receptor-2 with monoclonal antibodies or inhibition of receptor associated tyrosine kinase with low molecular weight inhibitors (cediranib, pazopanib, sorafenib or BIBF-1120).
Keywords: Bevacizumab, BIBF-1120, VEGF, Angiogenesis, Pazopanib, morphologic, endometrioid, carcinomas, morphologic continuum, tumor progression
Anti-Cancer Agents in Medicinal Chemistry
Title:Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer
Volume: 12 Issue: 8
Author(s): Parham Khosravi-Shahi and Luis Cabezon-Gutierrez
Affiliation:
Keywords: Bevacizumab, BIBF-1120, VEGF, Angiogenesis, Pazopanib, morphologic, endometrioid, carcinomas, morphologic continuum, tumor progression
Abstract: Epithelial ovarian cancer (EOC) accounts for approximately 80-90% of all ovarian cancers, and 75% of the patients are diagnosed with advanced disease (stage III and IV). Front-line systemic chemotherapy improves survival in women with advanced EOC; however, tumor recurrence occurs in almost all advanced EOC patients at a median of 15 months from diagnosis, and 5-year survival is estimated at 10 to 30%. Additionally, around 20% of patients do not respond to standard front-line therapy. Tumoral angiogenesis plays an important role in the pathogenesis of EOC, and its inhibition might improve survival in patients with advanced EOC. High-grade EOC is characterized by overexpression of vascular endothelial growth factor (VEGF), which drives dysfunctional tumor-associated angiogenesis, contributing to high interstitial pressure and increased vascular permeability. Diverse anti-angiogenic drugs are under investigation, and direct targeting of this pathway can be achieved by sequestration of VEGF protein using monoclonal antibodies (bevacizumab) or engineered binding site molecules (aflibercept), blockade of the VEGF receptor-2 with monoclonal antibodies or inhibition of receptor associated tyrosine kinase with low molecular weight inhibitors (cediranib, pazopanib, sorafenib or BIBF-1120).
Export Options
About this article
Cite this article as:
Khosravi-Shahi Parham and Cabezon-Gutierrez Luis, Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (8) . https://dx.doi.org/10.2174/187152012802650020
DOI https://dx.doi.org/10.2174/187152012802650020 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review
Current Drug Targets Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry Recent Advances in Biomaterials for Tissue Engineering and Controlled Drug Delivery
Current Pharmaceutical Biotechnology Formulation and Characterization of Genistein-loaded Nanostructured Lipid Carriers: Pharmacokinetic, Biodistribution and In vitro Cytotoxicity Studies
Current Drug Delivery Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Application of Bioinformatics for the Search of Novel Anti-Viral Therapies: Rational Design of Anti-Herpes Agents
Current Bioinformatics Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds The Biology and Medicinal Chemistry of Epothilones
Current Medicinal Chemistry - Anti-Cancer Agents Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design The Role of Biomarker Genes in the Diagnosis and Treatment of Nonsmall Cell Lung Cancer
Current Respiratory Medicine Reviews Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Current Cancer Drug Targets Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Editorial (Thematic Issue: Chemoresistance in Gynecologic Cancers)
Current Cancer Therapy Reviews Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery